A sulfonamide quinoline derivative, its preparation method and application
By developing sulfonamide quinoline derivatives that bind to glucocorticoid receptors, causing only transcriptional repression, the side effects of existing drugs are resolved, achieving highly selective and stable anti-inflammatory effects, making them suitable for the treatment of autoimmune diseases.
Patent Information
- Application Number
- CN202510627525.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-05-15
- Publication Date
- 2026-11-17
AI Technical Summary
Existing glucocorticoid drugs have significant side effects when treating inflammatory and autoimmune diseases, and the bioavailability and metabolic stability of compound B53 are insufficient, which limits its efficacy.
A class of sulfonamide quinoline derivatives has been developed that, by binding to glucocorticoid receptors, induce only downstream transcriptional repression and can be prepared into pharmaceutical compositions for the treatment of autoimmune diseases.
This compound binds selectively to glucocorticoid receptors, inhibiting downstream pro-inflammatory signaling pathways and exhibiting significant anti-inflammatory effects. It has no transcriptional activation activity, thus avoiding side effects, and its bioavailability and metabolic stability are superior to those of commercially available drugs.
Smart Images

Figure CN123106531A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of pharmaceutical technology, specifically to a sulfonamide quinoline derivative, its preparation method, and its application. Background Technology
[0002] Glucocorticoids (GCs) are a crucial class of regulatory molecules in the body, playing a vital role in regulating development, growth, metabolism, and immune function. They are the most important regulatory hormones for the body's stress response and are among the most widely used and effective anti-inflammatory and immunosuppressant drugs in clinical practice. Glucocorticoids are used as anti-inflammatory drugs to treat a variety of inflammations, from asthma to psoriasis, but their continued use is limited by serious side effects: hypertension and major metabolic side effects such as impaired glucose tolerance, muscle atrophy, thinning of the skin, and osteoporosis.
[0003] GCs primarily exert their therapeutic effects through glucocorticoid receptors (GR). Their mechanism of action is as follows: Unactivated GR binds to binding proteins such as HSP90 in the cytoplasm. Along with GC binding, the GR LBD conformation changes, releasing HSP, which then enters the nucleus via ligand binding. There, it acts as a transcription factor, activating or repressing transcription of downstream genes. Once in the nucleus, GR binds to GRE response elements (+GRE DNA) in a homodimerized form, inducing gene transcription. This pathway is known as the GR transcriptional activation pathway. Because the GRE transcriptional activation pathway is involved in human glucose metabolism, bone health, and endocrine function, it is currently considered a major cause of side effects from GC-based drugs. The GR transcriptional repression pathway activated by GC has two completely different transcriptional repression mechanisms. The first is called "tethered indirect transrepression," where a single-molecule glucocorticoid receptor interferes with downstream pro-inflammatory signaling pathways by binding to specific factors such as NF-κB (p65), AP1 (c-jun), or STAT3, rather than directly to DNA. This leads to a reduction in the production of inflammatory disease-related cytokines, chemokines, adhesion factors, matrix metalloproteinases, and cyclooxygenase-2 (COX-2). The second transcriptional repression mechanism involves ligand-activated GR directly binding to evolutionarily conserved (-)GREs [inverted repeat (IR)nGRE], resulting in GC-induced direct transcriptional repression. It is generally believed that the anti-inflammatory effects of GCs are associated with indirect transcriptional repression, while direct transcriptional repression and direct transcriptional activation are associated with side effects.
[0004] To address this issue, directly targeting GR only induces transcriptional repression, meaning that finding small molecule regulators with significant anti-inflammatory effects but no transcriptional activation is currently an important option for treating patients with inflammatory infections. In previous studies, our group synthesized 62 N-acyl-6-sulfonamide-tetrahydroquinoline derivatives, among which compound B53 showed high specificity for GR, exhibiting excellent transcriptional repressive activity without transcriptional activation, and effectively reducing the expression of inflammatory factors IL-6, IL-1β, and TNF-α (Dan Li, et al. Discovery and Optimization of N-Acyl-6-sulfonamide-tetrahydroquinoline Derivatives as Novel Non-Steroidal Selective Glucocorticoid Receptor Modulators. J. Med. Chem., 2022, 65: 15710-15724.). However, poor bioavailability (F < 5%) and metabolic stability (T < 5%) were found. 1 / 2 The pharmacokinetic activity of B53 was limited by a time of <0.5 h. Further modification of the compound is necessary to improve its pharmacokinetic properties. Summary of the Invention
[0005] The purpose of this invention is to provide a novel compound that has glucocorticoid receptor binding activity and causes only downstream transcriptional repression, and to apply it in the preparation of drugs for treating inflammatory and autoimmune diseases.
[0006] To achieve the above objectives, the present invention adopts the following technical solution:
[0007] This invention provides a sulfonamide quinoline derivative with a structural formula as shown in any of formulas (I)-(V), or as shown in any of formulas (2)-(4).
[0008]
[0009] Among them, R 1 Selected from substituted or unsubstituted alkyl, cycloalkyl, substituted or unsubstituted aryl, heterocyclic, and heteroaryl groups;
[0010] R 2 R 3 R 6 R 7 R 8 R 9 R 10 Selected from hydrogen, hydroxyl, halogen, methyl, methoxy, cyano, substituted or unsubstituted alkyl, cycloalkyl.
[0011] R 4 Selected from substituted or unsubstituted alkyl, cycloalkyl, C1-C4 alkoxycarbonyl, substituted or unsubstituted aryl, heterocyclic, and heteroaryl groups;
[0012] R 5 Selected from hydrogen, substituted or unsubstituted alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl;
[0013] The substituents on the alkyl group are selected from one or more of the following groups: halogen, nitro, cyano, amino, hydroxyl, mercapto, carboxyl, ester, aryl, and heterocyclic.
[0014] The substituents on the aryl group are selected from one or more of alkyl, methoxy, amide, halogen, nitro, cyano, amino, hydroxy, carboxyl, ester, aryl, and heterocyclic groups;
[0015] X is selected from S and O.
[0016] Terminology Explanation:
[0017] "Alkyl" refers to a straight-chain or branched hydrocarbon chain comprising 1-6 carbon atoms. Examples of "alkyl" as used in this invention include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, and substituted alkyl groups. In this invention, the alkyl group may optionally be substituted once or multiple times with a halogen or hydroxyl group, such as trifluoromethyl or other haloalkyl groups, hydroxymethyl or other hydroxylated alkyl groups.
[0018] "Alkoxy" refers to an -O-alkyl group, wherein the alkyl group is as defined above. Examples of "alkoxy" as used in this invention include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, and substituted alkoxy groups. The alkoxy groups described in this invention may optionally be substituted with halogens once or multiple times.
[0019] "Aryl" refers to an all-carbon monocyclic or fused polycyclic group with 5-12 carbon atoms, possessing a fully conjugated π-electron system. Non-limiting examples of aryl groups include: benzene rings, naphthalene rings, and anthracene rings.
[0020] "Heteroaryl" refers to a non-all-carbon monocyclic or fused polycyclic group with 5-12 carbon atoms and a fully conjugated π-electron system. Non-limiting examples of heteroaryl groups include: pyridine, imidazole, furan, thiazole, purine, indole, thiophene, and azaindole.
[0021] "Cycloalkyl" refers to a saturated carbon ring with 3-8 ring atoms. Examples of "cycloalkyl" used in this invention include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
[0022] "Halogen" refers to fluorine, chlorine, bromine, or iodine.
[0023] Furthermore, the structural formula of the sulfonamide quinoline derivative is shown in formula (1), or any one of formulas (5) to (43), respectively corresponding to compounds D1, D5-D43 in the specific embodiments;
[0024]
[0025]
[0026]
[0027] This invention provides a method for preparing the sulfonamide quinoline derivative, the method comprising:
[0028] Starting with 6-nitroquinoline, 6-nitrotetrahydroquinoline was obtained by reduction with B(OH)3 and Hantatzsch ester. Hydrogen was removed under NaH conditions, and intermediate 3 was obtained by nucleophilic substitution reaction with benzenesulfonyl chloride. The nitro group of the benzene ring was substituted and reduced with Pd / C and H2 to obtain intermediate 4. Using pyridine as an acid-binding agent, intermediate 4 was reacted with substituted benzenesulfonyl chloride to prepare a compound with the structural formula shown in formula (I).
[0029] Alternatively, starting with 2-chloro-5-nitrobenzoic acid, intermediate 18 is obtained by reacting it with β-alanine under K2CO3, AcONa, and (AcO)2Cu catalysis. Intermediate 18 is then reacted with Ac2O under K2CO3 as a base catalysis to generate intermediate 19. Intermediate 19 is deformylated under K2CO3 and MeOH as solvent reflux to obtain intermediate 20. Intermediate 20 undergoes a nucleophilic substitution reaction with benzyl bromide to generate intermediate 21. The nitro group of the benzene ring is reduced by Pd / C and H2 to obtain intermediate 22. Intermediate 22 is then reacted with substituted benzenesulfonyl chloride using pyridine as an acid-binding agent to prepare a compound with the structural formula shown in formula (II).
[0030] Alternatively, starting with 2-quinolinone, selective nitration with HNO3 and H2SO4 yields 6-nitroquinolinone. Under the condition of Cs2CO3 as a base, nucleophilic substitution reaction with substituted benzyl bromide or benzyl chloride yields an intermediate. The benzene ring substituted nitro group is selectively reduced with SnCl2 and then reacted with substituted benzenesulfonyl chloride under the condition of pyridine as a base to obtain a compound with the structural formula shown in formula (Ⅲ).
[0031] Alternatively, starting with acridinone, selective nitration with HNO3 and H2SO4 yields 6-nitroacinone. After dehydrogenation under K2CO3 conditions, nucleophilic substitution with benzyl bromide yields intermediate 27. The nitro group on the benzene ring is selectively reduced with Pd / C and H2 to generate intermediate 28. Intermediate 28 is then reacted with substituted benzenesulfonyl chloride under pyridine as a base to prepare a compound with the structural formula shown in formula (Ⅳ).
[0032] Alternatively, starting with 2-chloro-6-nitroquinoline, intermediate 30 is obtained through a nucleophilic substitution reaction with aniline; intermediate 30 is then subjected to Pd / C, H2 reduction of the nitro group to an amino group to obtain intermediate 31; intermediate 31 is then reacted with substituted benzenesulfonyl chloride under pyridine as a base to prepare a compound with the structural formula shown in formula (V).
[0033] This invention also provides the use of at least one of the aforementioned sulfonamide quinoline derivatives or their pharmaceutically acceptable salts, prodrug molecules, stereoisomers, deuterated derivatives, and solvates in the preparation of glucocorticoid receptor modulators. The glucocorticoid receptor modulators refer to those that target glucocorticoid receptors to induce downstream transcriptional repression. This invention demonstrates that the compounds can bind to glucocorticoid receptors with high selectivity, thereby inhibiting the activation of multiple downstream pro-inflammatory signaling pathways, including NF-κB and AP-1.
[0034] Furthermore, the present invention provides the use of at least one of the sulfonamide quinoline derivatives or their pharmaceutically acceptable salts, prodrug molecules, stereoisomers, deuterated derivatives, and solvates in the preparation of medicaments for treating autoimmune diseases. Specifically, the autoimmune diseases are caused by activation of the pro-inflammatory signaling pathways NF-κB and / or AP1.
[0035] Furthermore, the autoimmune diseases mentioned are at least one of the following: Alzheimer's disease, Parkinson's disease, atherosclerosis, asthma and allergic airway inflammation, atopic dermatitis, amyotrophic lateral sclerosis, cryoinflammatory factor-related periodic fever syndrome, gout, glomerulonephritis, inflammatory bowel disease, non-alcoholic fatty liver disease and non-alcoholic lipoic hepatitis, autoimmune hepatitis, hypertension, myocardial infarction, multiple sclerosis or autoimmune encephalitis, inflammatory nephropathy, influenza, organ transplant rejection, stroke, silicosis, traumatic brain injury, sepsis, rheumatoid arthritis, obesity-related inflammation or insulin resistance, type I or type II diabetes, osteoarthritis and osteoporosis, myelodysplastic syndrome, and allergic skin reactions.
[0036] The drug is formulated with the sulfonamide quinoline derivative or its pharmaceutically acceptable salt, prodrug molecule, stereoisomer, deuterated product, or solvate as the main active ingredient, and with the addition of a pharmaceutically acceptable carrier, in accordance with the formulation preparation method described in pharmaceutics.
[0037] Specifically, the present invention provides a pharmaceutical composition for treating autoimmune diseases, comprising at least one of the following as active ingredients: a sulfonamide quinoline derivative or a pharmaceutically acceptable salt thereof, a prodrug molecule, a stereoisomer, a deuterated derivative, a solvate, and a pharmaceutically acceptable carrier.
[0038] The sulfonamide quinoline derivatives or their pharmaceutically acceptable salts, prodrug molecules, stereoisomers, deuterated derivatives, and solvates in the pharmaceutical compositions provided by this invention can be used as the sole active ingredient to exert glucocorticoid receptor antagonistic effects, or they can be combined with other active substances that induce glucocorticoid receptor transcriptional inhibition.
[0039] Pharmaceutically acceptable salts include alkali metal salts, alkaline earth metal salts, other metal salts, inorganic alkali salts, organic alkali salts, inorganic acid salts such as lower alkyl sulfonates and aryl sulfonates, and organic acid salts such as amino acid salts.
[0040] Furthermore, the pharmaceutically acceptable salt is a hydrochloride, benzenesulfonate, methylbenzenesulfonate, phosphate, maleate, sulfate, acetate, citrate, fumarate, or tartrate.
[0041] In this invention, the pharmaceutical composition can be in the form of a gas, liquid, or solid formulation.
[0042] The pharmaceutically acceptable carriers refer to conventional drug carriers in the pharmaceutical field, including conventional diluents and excipients such as water, fillers such as starch, binders such as cellulose derivatives and gelatin, humectants such as glycerin, disintegrants such as agar and calcium carbonate, adsorbents such as kaolin and soap clay, surfactants such as hexadecyl alcohol, absorption promoters such as quaternary ammonium compounds, lubricants such as talc, and flavorings and sweeteners may be added when necessary.
[0043] The pharmaceutical formulations are suitable for administration via any suitable route, such as nasal spray, oral spray (inhaler), oral (including sublingual or sublingual administration), rectal administration, local administration (including sublingual, sublingual, or transdermal administration), vaginal administration, or parenteral administration (including subcutaneous, intramuscular, intravenous, or intradermal injection). The formulations described in this invention can be prepared by any method known in pharmaceutical science. For example, methods involving mixing the active ingredient with a carrier or excipient.
[0044] The beneficial effects of this invention are as follows:
[0045] This invention provides a novel class of compounds with glucocorticoid receptor binding activity that induce only downstream transcriptional repression. These compounds target the glucocorticoid receptor ligand domain, effectively inhibiting the activation of multiple downstream pro-inflammatory signaling pathways, including NF-κB and AP1, exhibiting significant anti-inflammatory effects. Furthermore, these compounds do not induce transcriptional activation, thus avoiding side effects caused by transcriptional activation. They are also non-cytotoxic and do not bind to other steroidal nuclear receptors. In addition, these compounds have high bioavailability and good in vivo metabolic stability, superior to commercially available drugs. Therefore, their application in the development of therapeutic drugs for glucocorticoid receptor-mediated autoimmune diseases has potential value. Attached Figure Description
[0046] Figure 1 This describes the synthetic route for the preparation of tetrahydroquinoline sulfonamide derivatives.
[0047] Figure 2 This describes the synthetic route for the preparation of tetrahydroquinoline sulfonamide derivative D2.
[0048] Figure 3 This describes the synthetic route for the preparation of tetrahydroquinoline sulfonamide derivative D3.
[0049] Figure 4 This describes the synthetic route for the preparation of tetrahydroquinoline sulfonamide derivative D4.
[0050] Figure 5 Synthetic route for the preparation of 4-carbonyl-1,2,3,4-tetrahydroquinoline derivatives.
[0051] Figure 6 Synthetic route for the preparation of 2-carbonyl-1,2,3,4-tetrahydroquinoline derivatives.
[0052] Figure 7 This describes the synthetic route for the preparation of acridinone quinoline derivatives.
[0053] Figure 8 This describes the synthetic route for the preparation of sulfonamide quinoline derivatives.
[0054] Figure 9 Synthetic routes for the preparation of sulfonamide quinolinone derivatives D35-D38.
[0055] Figure 10 Synthetic routes for the preparation of sulfonamide quinolinone derivatives D41-D43.
[0056] Figure 11 D6 inhibits the release of inflammatory factors in mouse macrophages.
[0057] Figure 12 To detect the effect of active compounds on OPG using RT-qPCR.
[0058] Figure 13 To detect the effect of active compounds on RANKL by RT-qPCR.
[0059] Figure 14 To detect the effect of active compounds on OPG / RANKL by RT-qPCR.
[0060] Figure 15 This refers to the selectivity of the active compound for the nuclear receptor AR.
[0061] Figure 16 This refers to the selectivity of the active compound for the nuclear receptor PR.
[0062] Figure 17 This refers to the selectivity of active compounds for the nuclear receptor MR.
[0063] Figure 18 This study evaluates the safety of the active compound in 3T3 cells.
[0064] Figure 19 Safety evaluation of the active compound in GES-1 cells.
[0065] Figure 20 Safety evaluation of the active compound in HepG2 cells.
[0066] Figure 21 The images show a mouse model of atopic dermatitis treated with compounds D6 and D17. A represents the experimental route design; B represents changes in body weight; C represents a photograph of the model; D represents the H&E staining results; E represents the back tissue score of the mice; and F represents the epidermal thickness shown in the H&E staining experiment.
[0067] Figure 22 Compounds D6 and D17 were used to treat AIH induced by concanavalin A in mice.
[0068] Figure 23 The effect of active compound D6 on the expression of GR-regulated inflammation-related target gene mRNA.
[0069] Figure 24 The effect of active compound D17 on the expression of GR-regulated inflammation-related target gene mRNA.
[0070] Figure 25 The effect of active compound D40 on the expression of GR-regulated inflammation-related target gene mRNA. Detailed Implementation
[0071] The present invention will be further described below with reference to specific embodiments. These embodiments are for illustrative purposes only and are not intended to limit the scope of the invention. Any modifications or substitutions made to the methods, steps, or conditions of the present invention without departing from the spirit and essence of the invention are within the scope of the invention.
[0072] Unless otherwise specified, the experimental methods used in the following examples are conventional methods; the materials and reagents used are commercially available unless otherwise specified.
[0073] Example 1: Preparation of tetrahydroquinoline sulfonamide derivatives
[0074] Reaction route I: such as Figure 1 As shown, using readily available and inexpensive 6-nitroquinoline 1 as the starting material, the pyridine ring in the quinoline structure was selectively reduced using B(OH)3 and Hantatzsch ester (HE) as reducing agents to obtain 6-nitro-1,2,3,4-tetrahydroquinoline product 2. The synthesis of intermediate 3 can be achieved by dehydrogenating a secondary amine with NaH in anhydrous THF at 0°C, followed by a nucleophilic substitution reaction with benzenesulfonyl chloride. For the reduction of the nitro group, we selected 10% Pd / C catalysis, H2 as the hydrogen source, and MeOH as the solvent at room temperature to obtain an almost equivalent reduction product 4. Finally, using the organic base pyridine as an acid-binding agent, different substituted sulfonyl chlorides were added dropwise to intermediate 4 at 0°C. After the addition was complete, the reaction was allowed to proceed to room temperature, and TLC monitoring revealed the formation of tetrahydroquinoline sulfonamide final products.
[0075] 1. Synthesis of intermediate 2
[0076]
[0077] Starting with 6-nitroquinoline 1 (1.74 g, 10.0 mmol), Hantatzsch ester (6.33 g, 25.0 mmol) and B(OH)3 (123.6 mg, 2.0 mmol) were added to a 250 mL single-necked flask, and 100 mL of dichloroethane (DCE) was added as a solvent. The reaction was heated to 60 °C and carried out overnight. After the starting material spot disappeared as monitored by TLC, an appropriate amount of silica gel was added as a sample, and the solvent DCE was removed under vacuum. The resulting crude product was separated by column chromatography to obtain the target product 2 (1.25 g, yield: 70%). 1HNMR(400MHz,Chloroform-d)δ8.04(s,1H),7.87(d,J=2.8Hz,1H),6.93(d,J=2.8Hz,1H), 3.69(t,J=6.4Hz,2H),2.68(t,J=6.8Hz,2H),1.89(p,J=6.8Hz,2H); MS(ESI):179.08[M+H] + .
[0078] 2. Synthesis of intermediate 3
[0079]
[0080] 6-Nitro-1,2,3,4-Tetrahydroquinoline 2 (890.5 mg, 5.0 mmol) and 60% NaH (800.0 mg, 20.0 mmol) were placed in a 100 mL double-necked flask under argon purging protection. 30 mL of anhydrous THF was added at 0 °C, and the reaction was continued at 0 °C after the addition was complete. After 0.5 h of reaction, benzenesulfonyl chloride (1.059 g, 6.0 mmol) was added dropwise at 0 °C. The reaction was allowed to proceed at room temperature for 2 h. After TLC monitoring to confirm complete reaction, 10 mL of water was added to quench the reaction. The mixture was extracted three times with EA / H₂O. The combined organic phases were washed with saturated brine, dried over anhydrous Na₂SO₄, and filtered. The filtrate was evaporated under vacuum to obtain the crude product, which was purified by column chromatography. The target compound 3 (1.27 g, yield: 80%) was obtained. 1 H NMR(500MHz,Chloroform-d)δ8.08(d,J=3.0Hz,1H),7.89(dd,J1=9.0Hz,J2=3.0Hz,1H),7.37(dd,J1=1.8Hz,J2=0.8Hz,1H),7.11–6. 99(m,2H),6.48(dd,J1=3.5Hz,J2=2.0Hz,1H),4.03–3.90(m,2H),2.93(t,J=7.0Hz,2H),2.09(q,J=6.5Hz,2H); MS(ESI):319.08[M+H] + .
[0081] 3. Synthesis of intermediate 4
[0082]
[0083] N-benzenesulfonyl-6-nitro-1,2,3,4-tetrahydroquinoline 3 (63.6 mg, 0.2 mmol) was placed in a Schlenk tube, and 10% Pd / C (6.0 mg) was added as a catalyst. 1 mL of MeOH was added as a solvent, and the mixture was substituted with H2. The reaction was carried out overnight at room temperature. TLC was performed after the starting material spots completely disappeared. The reaction solution was filtered through diatomaceous earth to remove Pd / C, and the solvent was evaporated under vacuum to obtain the equivalent product. 1 H NMR(400MHz,Chloroform-d)δ8.08(d,J=2.8Hz,1H),7.89(dd,J1=8.0Hz,J2=2.0Hz,1H),7.37(dd,J1=2.0Hz,J2=1.2Hz,1H),7.11–6.99(m,2 H), 6.48 (dd, J1 = 3.2Hz, J2 = 1.2Hz, 1H), 4.78 (s, 2H), 4.03–3.90 (m, 2H), 2.93 (t, J = 8.0Hz, 2H), 2.09 (q, J = 6.4Hz, 2H); MS (ESI): 289.10 [M+H] + .
[0084] 4. Synthesis of final product D1
[0085]
[0086] N-Benzenesulfonyl-6-amino-1,2,3,4-tetrahydroquinoline 4 (57.6 mg, 0.2 mmol) was placed in a Schlenk tube under argon purging protection. 1 mL of anhydrous DCM was added, followed by pyridine (32.0 μL, 0.4 mmol). 2-Methoxy-4-chloro-5-methylbenzenesulfonyl chloride (46.8 mg, 0.2 mmol), dissolved in 1 mL of anhydrous DCM, was slowly added dropwise at 0 °C. The mixture was allowed to react at room temperature for 2 h after the addition was complete. After the reaction was complete, silica gel was added and the mixture was stirred. Column chromatography yielded the final product D1 (yield: 86.0 mg, 85%).
[0087] 5. Synthesis of D2
[0088] like Figure 2 As shown, commercially available 2-methyl-6-nitroquinoline 5 was used as the starting material and reduced by B(OH)3 and Hantatzsch ester (HE) to obtain 2-methyl-6-nitrotetrahydroquinoline intermediate 6, which was then prepared by similar steps as D1 to obtain D2.
[0089] 6. Synthesis of D3
[0090] like Figure 3As shown, similar to step D1, intermediate 2 undergoes dehydrogenation under NaH conditions, followed by a nucleophilic substitution reaction of Cbz to give intermediate 9. The nitro group of the benzene ring is substituted and reduced by Pd / C, H2 to give intermediate 10. Intermediate 10 reacts with substituted benzenesulfonyl chloride under pyridine as a base to give D3 in high yield.
[0091] Example 2: Synthesis of sulfonamide compound D4, 4, dimethyltetrahydroquinoline
[0092] Reaction route: such as Figure 4 As shown, we used 3-methyl-N-phenylbut-2-enamide 11 as the starting material, and an intramolecular cyclization reaction catalyzed by AlCl3 yielded intermediate 12. Intermediate 12 underwent selective nitration with HNO3 and H2SO4 to give intermediate 13. Intermediate 13 underwent selective carbonyl reduction with BH3-THF to give intermediate 14. Under the condition of Cs2CO3 as a base, intermediate 14 underwent a nucleophilic substitution reaction with benzyl bromide to give intermediate 15. Intermediate 15 underwent a reduction and nucleophilic substitution step similar to that of D1 to give the final product D4.
[0093] 1. Synthesis of Intermediate 12
[0094] Starting with 3-methyl-N-phenylbut-2-enamide 11, compound 11 (1.0 g, 5.7 mmol) and AlCl3 (1.3 g, 8.6 mmol) were added to a 100 mL single-necked flask. 40 mL of DCE was added as solvent, and the reaction was heated to 100 °C for 2 h. After the reaction was completed by TLC, the pH of the reaction solution was adjusted to approximately 7 with 2 M HCl. The mixture was extracted three times with DCM / H2O, and the organic phases were combined, dried over anhydrous Na2SO4, and the solvent was evaporated under vacuum. The crude product was purified by column chromatography (PE / EA) to give a white solid product 12 (0.85 g, 68%). 1H NMR (400MHz, Chloroform-d) δ8.48 (s, 1H), 7.34–7.28 (m, 1H), 7.26–7.14 (m, 1H), 7.06 (q, J1=8.8Hz, J2=8.0Hz, 1H),6.82(t,J=9.2Hz,1H),2.58–2.45(m,2H),1.67(d,J=10.4Hz,1H),1.41–1.30(m,6H); MS(ESI):176.23[M+H] + .
[0095] 2. Synthesis of Intermediate 13
[0096] Compound 12 (0.85 g, 4.85 mmol) was added to a 50 mL single-necked flask and dissolved in 20 mL of concentrated H₂SO₄. The system was placed in an ice bath at 0 °C, and HNO₃ (458.4 mg, 7.3 mmol) was slowly added dropwise. After the addition was complete, the mixture was stirred in the ice bath for 0.5 h. Post-treatment: The reaction solution was slowly added to ice water with continuous stirring. A large amount of yellow solid precipitated as the crude product. The crude product was purified by column chromatography (PE / EA) to obtain a pale yellow solid product 13 (1.05 g, yield: 98%). MS (ESI): 221.09 [M+H] + .
[0097] 3. Synthesis of Intermediate 14
[0098] Compound 13 (750.0 mg, 3.4 mmol) was added to a 100 mL single-necked flask and dissolved in 20 mL of anhydrous THF. 20.4 mL of 1 M BH3-THF was added dropwise at room temperature. After the addition was complete, the reaction mixture was refluxed at 80 °C overnight. The reaction was monitored by TLC to confirm completion. The reaction was cooled to room temperature, quenched with 2 M HCl solution, and extracted three times with EA / H2O. The organic phases were combined, washed with saturated brine, dried over anhydrous Na2SO4, and the solvent was evaporated under vacuum to obtain the crude product. The crude product was purified by column chromatography (PE / EA) to give a pale yellow solid, product 14 (680.0 mg, yield: 97%). 1 HNMR(400MHz,Chloroform-d)δ8.11(d,J=2.4Hz,1H),7.88(dd,J1=8.8Hz,J2=2.4Hz,1H),6.3 8(d,J=9.2Hz,1H),3.48–3.42(m,2H),1.76–1.70(m,2H),1.32(s,6H).MS(ESI):207.11[M+H] + .
[0099] 4. Synthesis of Intermediate 15
[0100] Compound 14 (1.03 g, 5.0 mmol) was added to a 100 mL single-necked flask, along with 60% NaH (600 mg, 15.0 mmol) solid. 20 mL of anhydrous THF was added at 0 °C to dissolve the compound. The reaction was allowed to proceed for 30 min at 0 °C. Then, benzoyl chloride (913.7 mg, 6.5 mmol) dissolved in anhydrous THF was added, and the mixture was allowed to react at room temperature for 2 h. The reaction was monitored by TLC until completion. The reaction was cooled to room temperature, quenched with an aqueous solution, and extracted three times with EA / H₂O. The organic phases were combined, washed with saturated brine, dried over anhydrous Na₂SO₄, and the solvent was evaporated under vacuum to obtain the crude product. The crude product was purified by column chromatography (PE / EA) to yield a white solid, product 15 (1.16 g, yield: 75%). MS (ESI): 311.11 [M+H] + .
[0101] 5. The specific synthesis steps of intermediate 16 and final product D4 are similar to those of compound 4 and final product D1 in Example 1.
[0102] Example 3: Preparation of sulfonamide 4-carbonyl-1,2,3,4-tetrahydroquinoline derivative D5
[0103] Reaction route II, such as Figure 5 As shown: Starting with 2-chloro-5-nitrobenzoic acid 17, intermediate 18 was obtained by reacting with β-alanine under the catalytic conditions of K2CO3, AcONa, and (AcO)2Cu. Intermediate 18 was then reacted with Ac2O under the catalysis of K2CO3 as a base to generate intermediate 19. Intermediate 19 was then deformylated under the reflux conditions of K2CO3 and MeOH as solvents to obtain intermediate 20. Finally, the final product D5 was obtained through steps similar to those in D1.
[0104] 1. Synthesis of intermediate 18
[0105]
[0106] 2-Chloro-5-nitrobenzoic acid 17 (2.0 g, 10.0 mmol), β-alanine (0.9 g, 10.0 mmol), K₂CO₃ (2.1 g, 15.0 mmol), AcONa (0.9 g, 11.0 mmol), and Cu(AcO)₂ (182.0 mg, 1.0 mmol) were added to a 100 mL two-necked flask, followed by 40 mL of isopropanol. After the addition was complete, the reaction mixture was heated to 100 °C for 3 h. The reaction was monitored by TLC until complete. The reaction mixture was filtered, and the filter cake was washed with acetone to obtain a yellow solid crude product. The crude product was dissolved in hot 0.1 M NaOH solution, stirred, and filtered while hot. The filtrate was adjusted to pH 3 with 2 M HCl, resulting in the precipitation of a large amount of yellow solid. The solid was filtered and dried to obtain a pale yellow solid product 18 (1.48 g, yield: 58%).
[0107] 2. Synthesis of Intermediate 19
[0108]
[0109] Compound 18 (1.0 g, 4.0 mmol) and K₂CO₃ (1.1 g, 8.0 mmol) were placed in a 100 mL single-necked flask, and 40 mL of Ac₂O was added as solvent. After the addition was complete, the reaction mixture was refluxed at 100 °C overnight. The reaction was monitored by TLC, and the mixture was extracted with EA / H₂O. The organic phases were combined, washed with saturated brine, dried over anhydrous Na₂SO₄, and the solvent was evaporated under vacuum. The mixture was then purified by column chromatography (DCM / MeOH) to give product 19 (481.2 mg, yield: 50%). 1 H NMR (400MHz, Chloroform-d) δ8.86 (d, J=2.8Hz, 1H), 8.37 (dd, J1=9.2Hz, J2=2.8Hz, 1H), 7.92 (d, J= 9.2Hz,1H),4.32-4.21(m,2H),2.95-2.88(m,2H),2.46(s,3H),2.12(s,1H).MS(ESI):255.06[M+H] + .
[0110] 3. Synthesis of Intermediate 20
[0111]
[0112] Compound 19 (481.0 mg, 1.9 mmol) and K2CO3 (525.0 mg, 3.8 mmol) were placed in a 100 mL single-necked flask, and 40 mL of MeOH was added as solvent. After the addition was complete, the reaction mixture was refluxed at 80 °C overnight. The reaction was monitored by TLC, and the mixture was extracted with EA / H2O. The organic phases were combined, washed with saturated brine, dried over anhydrous Na2SO4, and the solvent was evaporated under vacuum. The mixture was then purified by column chromatography (DCM / MeOH) to give a yellow solid product 20 (150.1 mg, yield: 41%). 1 H NMR (400MHz, DMSO-d6) δ8.37(d,J=2.8Hz,1H),8.30(s,1H),8.08(dd,J1=9.2Hz,J2=2.8Hz,1H),6.8 6(d,J=9.2Hz,1H),3.60(td,J1=7.2Hz,J2=2.4Hz,2H),2.65(t,J=7.2Hz,2H).MS(ESI):193.06[M+H] + .
[0113] 4. Synthesis of intermediate 21
[0114]
[0115] Compound 20 (480.0 mg, 2.0 mmol) was placed in a 100 mL single-necked flask, and Cs₂CO₃ (2.0 g, 6.0 mmol) was added. 40 mL of DMF was added as a solvent to dissolve the compound. 0.4 mL of benzyl bromide was added at room temperature, and the reaction mixture was then moved to 80 °C for 2 h. After the reaction was completed by TLC, the mixture was cooled to room temperature, extracted three times with EA / H₂O, and the organic phases were combined. The organic phase was washed with saturated brine and dilute hydrochloric acid, dried over anhydrous Na₂SO₄, and the solvent was evaporated under vacuum. The resulting product was purified by column chromatography to give a yellow solid, product 21 (363.3 mg, yield: 55%).
[0116] 5. The specific synthesis steps of compound 22 and final product D5 are similar to those of compound 4 and final product D1 in Example 1.
[0117] Example 4: Preparation of sulfonamide 2-carbonyl-1,2,3,4-tetrahydroquinoline derivatives
[0118] Reaction route III, such as Figure 6As shown: Starting with 2-quinolinone 23, selective nitration with HNO3 and H2SO4 yields 6-nitroquinolinone intermediate 24. Under Cs2CO3 as a base, nucleophilic substitution reactions with various substituted benzyl bromides or chlorinated derivatives yield the corresponding intermediates. The nitro group on the benzene ring is selectively reduced with SnCl2 to generate aniline intermediates. These aniline intermediates, under pyridine as a base, react with substituted benzenesulfonyl chlorides to give the final products D6, D9-D34, and D39-D40.
[0119] 1. Synthesis of chlorinated products
[0120]
[0121] Hydroxymethylcyclopropane (144.2 mg, 2.0 mmol) was placed in a 10 mL round-bottom flask, and 5 mL of SOCl2 was added. The mixture was stirred at 100°C for 2 h. After the reaction was completed by TLC, the solvent was evaporated under vacuum, and the crude product (PE / EA) was purified by column chromatography to obtain the chlorinated product (86.6 mg, yield: 42%).
[0122] 2. The synthesis of intermediate 24 and final products D6, D9-D34, D39-D40 is similar to that in Example 2.
[0123] 3. Synthesis of D35-D38
[0124] like Figure 9 As shown, commercially available p-fluorobenzaldehyde 33 undergoes a nucleophilic substitution reaction with a secondary amine under the catalysis of K2CO3 to generate intermediate 34a-d. Intermediate 34a-d is selectively reduced to alcohol 35a-d using NaBH4. Then, using the Mitsunobu reaction with PPh3 and DEAD as catalysts, alcohol 35a-d reacts with secondary amine 32 to generate intermediate 36a-d. The nitro group is reduced by SnCl2, followed by nucleophilic substitution with benzenesulfonyl chloride to obtain the final products D35-D38.
[0125] 4. Synthesis of D41-D43
[0126] like Figure 10 As shown, 1-(4-methylphenyl)-1-ethanol 38 and compound 32 undergo a Mitsunobu reaction to generate intermediate 39. The nitro group of intermediate 39 is reduced by SnCl2, followed by nucleophilic substitution with benzenesulfonyl chloride to obtain the final products D41-D43. Using chiral starting materials (R)-phenylethanol and (S)-phenylethanol, and based on the chirality reversal characteristics of the Mitsunobu reaction, chiral final products D41-D43 can be prepared.
[0127] Example 5: Preparation of acridinone quinoline sulfonamide derivatives (IV)
[0128] Reaction route IV, such as Figure 7 As shown: Starting with commercially available acridinone 25, selective nitration with HNO3 and H2SO4 yields 6-nitroacinone intermediate 26. Hydrogen removal in the presence of K2CO3 followed by nucleophilic substitution with benzyl bromide yields intermediate 27. The nitro group on the benzene ring is selectively reduced with SnCl2 to generate intermediate 28. Under pyridine as a base, intermediate 28 reacts with substituted benzenesulfonyl chloride to give the final product D7 in high yield.
[0129] 1. Synthesis of intermediate 26
[0130]
[0131] Compound 25 (975.0 mg, 5.0 mmol) was placed in a 100 mL single-necked flask and dissolved in 20 mL of concentrated HNO3. After the addition was complete, the reaction was carried out in an ice bath at 0 °C, and 5 mL of AcOH was added dropwise. After the addition was complete, the reaction was continued at 0 °C for 0.5 h. The reaction was monitored by TLC to indicate completion. Post-treatment: The reaction solution was slowly added to ice water with constant stirring. A large amount of yellow solid precipitated as the crude product. The crude product was purified by column chromatography (PE / EA) to give a bright yellow solid product 26 (1.12 g, yield: 92%). MS (ESI): 241.06 [M+H] + .
[0132] 2. Synthesis of intermediate 27
[0133]
[0134] Compound 26 (480.4 mg, 2.0 mmol) was placed in a 100 mL single-necked flask, and Cs₂CO₃ (2.0 g, 6.0 mmol) was added and dissolved in 40 mL of DMF. 0.4 mL of benzyl bromide was added at room temperature, and the reaction mixture was then moved to 80 °C for 2 h. After the reaction was completed by TLC, the mixture was cooled to room temperature, extracted three times with EA / H₂O, and the organic phases were combined. The organic phase was washed with saturated brine and dilute hydrochloric acid, dried over anhydrous Na₂SO₄, and the solvent was evaporated under vacuum. The resulting product was purified by column chromatography to give a yellow solid, product 27 (429.1 mg, yield: 65%).
[0135] 3. The synthesis of intermediate 28 and final product D7 is similar to that in Example 2.
[0136] Example 6: Preparation of compound D8
[0137] Reaction route V, such as Figure 8As shown: Starting from 2-chloro-6-nitroquinoline 29, intermediate 30 was obtained through a nucleophilic substitution reaction with aniline. Intermediate 30 was then subjected to Pd / C, H2 reduction of the nitro group to an amino group to give intermediate 31. Intermediate 31 was then reacted with substituted benzenesulfonyl chloride under pyridine as a base to give compound D8 in high yield.
[0138] Test Example 1: Evaluation Experiment of Anti-inflammatory Capacity of Glucocorticoid Receptors
[0139] Detection Principle: Glucocorticoids exert their anti-inflammatory effects primarily through transcriptional repression—specifically, inhibiting the NF-κB (p65) and AP-1 (c-jun) signaling pathways, leading to a decrease in the expression of inflammatory factors. The dual-luciferase reporter gene assay system is sensitive, measuring two separate luciferase reporter genes in one system: firefly luciferase and marine renin luciferase. Marine renin luciferase exhibits stable expression in different types of mammalian cells, and its expression activity is insensitive to external drug stimulation, which can be used to correct for errors caused by varying transfection efficiencies. Therefore, in the dual-luciferase reporter gene assay, Renilla luciferase serves as a control reporter gene, providing normalization for the Firefly luciferase assay. Higher levels of inhibitory activity against NF-κB or AP-1 by the test compound result in a smaller Firefly luciferase / Renilla luciferase ratio, indicating a stronger anti-inflammatory ability of the measured compound.
[0140] Detection steps: In the detection method of this invention, cervical cancer cells (HeLa) are analyzed at a concentration of 1×10⁻⁶. 4 Cells were seeded at a density of [number] cells / well in clear 96-well plates. After stable cell adhesion, HeLa cells were co-transfected with full-length human GRα protein, pNF-κB-luc, and Renilla (pRL-TK) using Lipofectamine 3000. 24 h after transfection, cells were treated with 5 ng / ml TNFα and 10 μM assay compound, respectively. After 18 h, the cell culture plate was removed, washed twice with PBS, and the waste solution was discarded. 20 μL of 1×PLB lysis buffer (30 μL per well) was added to each well. The cell culture plate was incubated on a shaker for 30 minutes for complete lysis. The relative luciferase content in each well was measured using a microplate reader to determine the Fireflyluciferase / Renilla luciferase ratio.
[0141] Results: The transcriptional repressive activities of the compounds against NF-κB and AP-1 are shown in Table 1. Most compounds exhibited good transcriptional repressive activity against NF-κB and AP-1. D6 showed the strongest inhibitory activity against both NF-κB and AP-1 among the tested compounds, with an IC50 of [missing value]. 50 The values are 0.9 nM and 0.5 nM, respectively.
[0142] Table 1. Screening of chemical structures and bioactivities of some dihydroquinoline sulfonamide compounds.
[0143]
[0144]
[0145] Note: ND: Not detected. When the TR of a certain compound... NF-κB and TR Ap-1 IC 50 When the values are all greater than 10 μM, the GR binding IC of this compound is 50 The value cannot be determined. NA: Inactive. The TA of the compound. antag IC 50 The value is greater than 100 μM.
[0146] Test Example 2: Competitive Binding Experiment of Glucocorticoid Receptor to Verify the Binding Strength to the Target
[0147] Detection principle: Invitrogen's time-resolved fluorescence resonance energy transfer (TR-FRET) technology was used to detect the binding affinity of compounds to glucocorticoid receptors. When performing... When performing TR-FRET GR competitive binding assay, Fluormone was added. TM GS1 Green tracer was added to the ligand test compound or solvent control, followed by the addition of a mixture of GR-LBD (GST) and Tb-anti-GST antibody. After incubation at room temperature for 2 hours, readings were taken at 520 nm and 495 nm, respectively, and the TR-FRET ratio was calculated to be 520:495. This ratio can be used to determine the IC50 based on the compound's dose-response curve. 50 If the competitive ligand of the test compound competes for the ligand in the ternary complex, the ratio value will decrease. If it does not target the site, the value will remain at its original level. Using the above principle, the targeting binding ability of a compound to the glucocorticoid receptor can be quantitatively determined.
[0148] Detection procedure: A mixture of glucocorticoid receptor ligand-binding domain {GR-LBD(His-GST)} and Tb-anti-GST antibody is mixed with analyte compounds at different concentration gradients, and then a fluorescent ligand (Fluormone) is added.TM GS1Green was used, with 10 μM dexamethasone as a positive control. Changes in ratio were detected using a multi-functional microplate reader to quantify whether compounds with high antagonistic activity accurately targeted glucocorticoid receptors.
[0149] Detection results: As shown in Table 1, compounds D1, D4, D5, D6, D17, D39 and D40 all showed high targeting ability of glucocorticoid receptor ligand domains.
[0150] Test Example 3: D6 inhibits the release of inflammatory factors in macrophages
[0151] Detection principle: In inflammatory responses, LPS stimulates macrophages to release a large number of inflammatory factors, leading to excessive inflammation and organ damage. Therefore, inhibiting excessive inflammation is crucial for screening anti-inflammatory drugs. LPS-induced mouse peritoneal macrophage models are frequently used for screening anti-inflammatory drugs.
[0152] Detection Procedure: Extracted mouse peritoneal macrophages were cultured overnight, then the culture medium was replaced. 1 μL of the 10 mM test compound was added (final concentration 10 μM). For the negative control, an equal volume of DMSO was added and incubated for 30 min, followed by 1 μL of 0.5 mg / mL LPS solution (final concentration 0.5 μg / mL). The blank control was not stimulated with LPS solution. Culture was continued for 24 h. The culture medium from each well was transferred to EP tubes at 4°C and stored at -80°C for subsequent detection of TNF-α and IL-6 levels using ELISA.
[0153] Test results: such as Figure 11 As shown, compound D6 exhibited good inhibitory effects against the inflammatory factors TNF-α and IL-6, and at a drug concentration of 10 μM, its efficacy was comparable to that of the MD2 inhibitor L6H21 (TNF-α and IL-6 inhibition rates were 36.0% and 42.9%, respectively). Further calculations were made of the IC50 of compound D6. 50 The values were 7.74 μM and 6.90 μM, respectively.
[0154] Test Example 4: Real-time quantitative PCR (RT-qPCR) assay to detect the effect of compounds on OPG / RANKL
[0155] Detection Principle: Osteoporosis is one of the main adverse reactions caused by GCs. Although the mechanism of GC-induced osteoporosis is not yet clear, the imbalance between bone resorption and formation is currently the most widely accepted mechanism. OPG is a glycoprotein that specifically inhibits osteoclast differentiation; RANKL can promote osteoclast differentiation and is an essential factor for enhancing the differentiation of mature osteoclast precursors into mature osteoclasts. An increase in OPG / RANKL is beneficial to bone formation, while a decrease is beneficial to osteoclast formation and promotes bone loss. To assess whether the compound would cause GC-like side effects such as bone loss and osteoporosis, the effects of the compound on the mRNA expression levels of OPG, RANKL, and OPG / RANKL in human osteoblasts MG-63 were investigated.
[0156] Detection steps: MG-63 cells were cultured at a concentration of 3 × 10⁻⁶. 5 Cells were seeded per well in 12-well plates, and drug was administered according to experimental requirements. Cells were then incubated. The old culture medium was discarded, and 200 μL of Buffer Lysis-DR was added. Cells were lysed at room temperature for 2 min, and total RNA was extracted. RNA purity was assessed, cDNA was reverse transcribed, and the cells were subjected to qPCR.
[0157] Test results: such as Figures 12-14 As shown, D6, D17, and D40 had effects on the mRNA expression levels of OPG, RANKL, and OPG / RANKL in cells. Although D6, D40, AZD 9567, and Dex all inhibited OPG mRNA expression, the OPG mRNA expression levels in the D6, D17, and D40 treatment groups were relatively higher than those in the Dex and AZD 9567 treatment groups. RANKL expression levels did not differ significantly among the groups, while the OPG / RANKL results were similar to those for OPG. In our experiments, although D6, D40, Dex, and AZD9567 all significantly inhibited OPG, the inhibitory effects of D6 and D40 were significantly weaker than those of Dex and AZD 9567, suggesting that D6 and D40 may reduce the risk of bone loss.
[0158] Test Example 5: Effects on other nuclear receptors
[0159] Detection principle: Nuclear receptor family proteins have high homology, and the selectivity of ligands determines whether the drug will be off-target and cause adverse drug reactions.
[0160] Testing steps:
[0161] 1) For MR assays: Stable transfected LNCaP cells were used, in which PLJM1-ARR2PB-EGFP was transfected into the cells. A gradient concentration of the analyte compound was added to each well.
[0162] 2) For PR assay: PC3 cells were co-transfected with 50 ng hPR (progesterone receptor), 50 ng ARR3tk luciferase, and 5 ng Renilla. A gradient concentration of the test compound was added to each well.
[0163] 3) For AR assay: PC3 cells were co-transfected with 71 ng pCMV-h MR, 24 ng pGL4.36 [luc2P-MMMTV-Hygro], and 5 ng Renilla. After 72 h of incubation, fluorescence was measured using a Synergy H1 instrument at an excitation wavelength of 485 nm and an emission wavelength of 535 nm.
[0164] 4) For MR and PR assays: luciferase activity was measured after 16 hours of incubation.
[0165] 5) Control wells were set on each plate, one containing 10 nM DMSO and the other containing a hormone stimulant to define 0% and 100% activation effects. The hormones used to stimulate AR, PR, and MR were DHT (dihydrotestosterone), progesterone, and aldosterone, respectively.
[0166] 6) Calculate the activation activity percentage of the raw data according to the following formula: Activation activity % = 100 × (value of test compound - value of DMSO group) / (value of hormone stimulation group - value of DMSO group).
[0167] Test results: such as Figures 15-17 The results show the activation effects of different concentrations of Dex and the compound on AR, PR, and MR. The results indicate that D6, D17, D31, and D40 did not activate other nuclear receptors (AR, PR, and MR), suggesting that D6, D17, D31, and D40 have good selectivity for GR; while Dex showed strong activation of these three nuclear receptors. The experimental results demonstrate that D6 has better selectivity for GR than Dex, while also avoiding off-target side effects, making it a potential candidate for development as a highly selective SGRM drug.
[0168] Test Example 6: Security Evaluation
[0169] Detection principle: The toxicity of the compound was evaluated using human gastrointestinal epithelial cells GES-1, human hepatocytes HepG2, and mouse fibroblast embryonic cells 3T3.
[0170] Testing steps:
[0171] 1) Cell preparation: Wash the cells in the culture flask with PBS buffer and centrifuge at 4°C and 1000 rpm for 5 min. Resuspend the cells and count them using a cell counting chamber. Dilute the cells to 5 × 10⁶ cells / mL. 4The cells were seeded at a density of 100 μL (5000 cells / well) into 96-well plates. The plates were incubated in a cell culture incubator for 24 hours, after which the culture medium was replaced with fresh medium.
[0172] 2) Add the test compound: Add 1 μL of 1 mM test compound (i.e., final concentration 10 μM), and simultaneously add an equal amount of DMSO as a negative control in one control well. Incubate the plate for another 72 h. Set up 3 replicates for each test compound concentration, and add PBS buffer around the perimeter of the 96-well plate to prevent edge effects.
[0173] 3) Add MTT solution: Add 15 μL of the prepared MTT solution to each well of a 96-well plate, and then place the plate in a cell culture incubator for 4 hours.
[0174] 4) Add dissolution buffer: Add 100 μL of SDS-HCl-PBS triple buffer to each well and incubate overnight in a cell culture incubator to fully dissolve the crystals formed by MTT.
[0175] 5) Cell viability detection: The absorbance (OD value) was measured at a wavelength of 570 nm using a microplate reader, and the cell viability was calculated. Cell viability was calculated by comparing the absorbance values of the compound-treated group and the negative control group. A lower cell viability indicates greater toxicity of the compound to the cells.
[0176] Test results: such as Figures 18-20 As shown, AZD 9567 exhibited toxicity in all three cell lines, while Dex, D6, D17, D39, and D40 showed no toxicity in any of the three cell models. This indicates that D6, D17, D39, and D40 are safe and effective SGRMs and can be further developed.
[0177] Test Example 7: Therapeutic effects of active compounds D6 and D17 on atopic dermatitis in mice
[0178] Detection Principle: Atopic dermatitis (AD) is a representative inflammatory skin disease that activates both innate and adaptive immune responses. Under the attack of allergens and pathogens, the skin's epithelial barrier reacts immediately, manifesting as eczema, severe itching, and widespread redness of the skin. To further evaluate the in vivo anti-inflammatory effects of the active compounds, we used a mouse AD model induced by 2,4-dinitrochlorobenzene (DNCB) and treated the mice with Dex (positive control) and the active compounds D6 and D17 for 21 consecutive days.
[0179] Detection Procedure: BALB / c mice of similar body weight were randomly divided into 6 groups: control group, model group, Dex administration group (positive control drug: 1.0 mg / kg), B53 administration group (20 mg / kg), D6 administration group (20 mg / kg), and D17 administration group (20 mg / kg). The day before the experiment, the backs of the mice were shaved with electric shears for DNCB sensitization. B53 and Dex were dissolved in 5% CMC-Na solution at appropriate concentrations and administered to the mice via gavage. The experimental schedule for DNCB-induced mouse specific dermatitis was established as follows: Figure 21 (A) shows the results. First, a 4:1 (v / v) mixture of 0.5% DNCB and 1% DNCA was prepared using acetone-olive oil solution. 200 μL of this solution was applied to the shaved areas of the control group mice, designated as day 0 (D0). From day 0 to 3, 100 μL each of 0.5% DNCB and 1% DNCA were applied to the shaved back skin of the mice to stimulate and induce atopic dermatitis. Starting on day 3, 100 μL of 1% DNCB was applied to the exposed back skin of the mice every 3 days to maintain the induced atopic dermatitis. Starting on day 4, the treatment group began receiving the experimentally determined dose via gavage once daily for 21 consecutive days. Skin lesions on the back of the mice were recorded according to the clinical skin scoring criteria: erythema / hemoptysis, scarring / dryness, edema, and exfoliation / erosion. Each level was scored from 0 to 3 (0, none; 1, mild; 2, moderate; 3, severe). The clinical skin score was defined as the sum of the scores, ranging from 0 to 12. Mouse skin tissue was fixed in 10% formalin, embedded in paraffin, and cut into 3 μm thick sections. The sections were stained with H&E to detect inflammatory cells.
[0180] Test results: such as Figure 21 As shown, no significant weight loss was observed in any group, indicating that the active compounds were non-toxic as a treatment for dermatitis in the mouse model. Then, the application of DNCB was observed to cause severe erythema, hemorrhage, and scarring in AD mice. However, treatment with D6 and D17 significantly alleviated the skin lesions on the back compared to AD mice. To further validate the effects of D6 and D17, we performed histological analysis by H&E staining. As expected, significant skin lesions were observed in the skin of AD mice, characterized by epidermal rupture and increased skin thickness. Treatment with D6 and D17 significantly improved skin lesions in a dose-dependent manner, suggesting potential for development as a treatment for mouse-specific dermatitis. Test Example 8: Effects of active compounds D6 and D17 on mouse immune-mediated hepatitis.
[0181] Detection principle: Autoimmune hepatitis (AIH) is an immune-mediated liver injury, and its liver inflammation is mostly chronic and progressive. In order to further evaluate the in vivo anti-inflammatory effect of active compounds, we used a mouse AIH model induced by concanavalin A (9 mg / kg, IV) and treated it with Dex (positive control) and active compounds D6 and D17 for 21 consecutive days. We also collected mouse serum to detect AST, ALT and liver pathological sections.
[0182] Detection Procedure: BALB / c mice of similar body weight were randomly divided into six groups: control group, model group, Dex administration group (positive control drug: 1.0 mg / kg), B53 administration group (50 mg / kg), D6 administration group (50 mg / kg), and D17 administration group (50 mg / kg). The administration groups were pre-administered with the test drug, followed by intravenous administration of concanavalin A (9 mg / kg, IV) via tail vein to establish an AIH model in mice. After 12 hours, blood was collected from the orbital cavity to measure ALT and AST levels; after 24 hours, blood was collected from the eyeballs, and liver tissue was harvested from the mice.
[0183] Test results: such as Figure 22 As shown, B53 did not show a significant therapeutic effect in this experiment. D6 was superior to D17 and had a better therapeutic effect on AIH. Furthermore, as the time increased (from 12h to 24h), the efficacy of D6 and D17 was better, and there was a more significant statistical difference compared with the model group.
[0184] Test Example 9: Effects of active compounds on mRNA expression in the GR-related signaling pathway
[0185] Detection principle: The glucocorticoid receptor (GR) signaling pathway plays an important role in cellular stress response, immune regulation, and metabolic regulation. Genes related to the GR signaling pathway include IL-1β, COX-2, TSLP, CLL-2, MMP-13, and GILZ.
[0186] Detection procedure: RAW264.7 cells in good growth condition were subjected to a 3×10⁻⁶ incubation process. 5 Cells were seeded into 12-well plates and incubated overnight for cell adhesion. After incubation with the target compound for 2 hours, LPS (10 ng / mL) was added, and the cells were cultured for another 24 hours. Total RNA was extracted and reverse transcribed into DNA. RT-qPCR was performed using appropriate primers. The mRNA expression of GR signaling pathway-related inflammatory genes IL-6, IL-1β, COX-2, CSF-2, CCL-2, MMP-13, and GILZ was detected. Primer sequences are shown in Table 2.
[0187] Table 2
[0188]
[0189] Test results: such as Figures 23-25 As shown, at the gene level, D6, D17, and D40 can all inhibit the expression of LPS-induced inflammatory factors TNF-α, IL-1β, and IL-6 in RAW264.7 to varying degrees, while reducing the mRNA expression of TSLP, MMP-13, and CCL-2, and having little effect on the mRNA expression of GILZ.
[0190] Test Example 10: Liver Microsomal Metabolic Stability Test
[0191] Detection principle: The human liver microsomal metabolic stability assay is mainly used to assess the metabolic stability of compounds in the liver, predict their metabolic rate and half-life in vivo, and thus provide important pharmacokinetic data for drug development.
[0192] Detection Procedure: The analyte is mixed with liver microsomes, cofactor (e.g., NADPH), and buffer solution to form a reaction system. NADPH acts as an electron donor, providing reducing power to the CYP450 enzyme and promoting the metabolic reaction. Incubation: The reaction system is incubated at 37°C for specific times (0, 5, 15, 30, 60 min). After the predetermined time, pre-cooled acetonitrile is added to stop the reaction. Samples are centrifuged and stored at -80°C. The remaining drug amount is identified by LC-MS.
[0193] Results: As shown in Table 3, in the human liver microsomal stability experiment, B53 had a half-life of 18.0 min, and after 60 min of human liver microsomal metabolism, only 9.1% of the drug remained unchanged. D6, D17, and D40, as novel parent nuclei SGRMs, exhibited better stability in human liver microsomes than B53. The half-lives of D6 and D17 reached 39.4 min and 31.7 min, respectively, and after 60 min of human liver microsomal metabolism, 32.0% and 31.9% of the original drug remained, respectively. Notably, in the human liver microsomal stability experiment, D6 and D17 demonstrated better metabolic stability than the marketed drugs testosterone, diclofenac, and propafenone.
[0194] Table 3. Stability analysis of active compounds and B53 in human liver microsomes.
[0195]
[0196] Note: NCF: No NADPH; T 1 / 2 Half-life; CL int(mic) =0.693 / T 1 / 2 / Microsomal protein content (mg / mL); CL int(liver) =CL int(mic) × Microsomal protein content in the liver (mg / g) × Liver weight to body weight ratio
[0197] The above description is merely an embodiment of the present invention and is not intended to limit the invention. Various modifications and variations can be made to the present invention by those skilled in the art. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principle of the present invention should be included within the scope of the claims of the present invention.
Claims
1. A sulfonamide quinoline derivative, characterized by, The structural formulas of the sulfonamide quinoline derivatives are shown in any of formulas (I)-(V), or in any of formulas (2)-(4). wherein R 1 is selected from substituted or unsubstituted alkyl, cycloalkyl, substituted or unsubstituted aryl, heterocyclyl, heteroaryl; R 2 , R 3 , R 6 , R 7 , R 8 , R 9 , R 10 is selected from the group consisting of hydrogen, hydroxyl, halogen, methyl, methoxy, cyano, substituted or unsubstituted alkyl, cycloalkyl; R 4 selected from substituted or unsubstituted alkyl, cycloalkyl, C1-C4alkoxycarbonyl, substituted or unsubstituted aryl, heterocyclyl, heteroaryl; R 5 selected from hydrogen, substituted or unsubstituted alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl; The substituents on the alkyl group are selected from one or more of the following groups: halogen, nitro, cyano, amino, hydroxyl, mercapto, carboxyl, ester, aryl, and heterocyclic. The substituents on the aryl group are selected from one or more of alkyl, methoxy, amide, halogen, nitro, cyano, amino, hydroxy, carboxyl, ester, aryl, and heterocyclic groups; X is selected from S and O.
2. The sulfonamide quinoline derivative according to claim 1, wherein The structural formula of the sulfonamide quinoline derivative is shown in formula (1), or any one of formulas (5)-(43).
3. The method of preparing a sulfonamide quinoline derivative according to claim 1 or 2, wherein include: Starting with 6-nitroquinoline, 6-nitrotetrahydroquinoline was obtained by reduction with B(OH)3 and Hantatzsch ester. Hydrogen was removed under NaH conditions, and intermediate 3 was obtained by nucleophilic substitution reaction with benzenesulfonyl chloride. The nitro group of the benzene ring was substituted and reduced with Pd / C and H2 to obtain intermediate 4. Using pyridine as an acid-binding agent, intermediate 4 was reacted with substituted benzenesulfonyl chloride to prepare a compound with the structural formula shown in formula (I). Alternatively, starting with 2-chloro-5-nitrobenzoic acid, intermediate 18 is obtained by reacting with β-alanine under K2CO3, AcONa, and (AcO)2Cu catalysis. Intermediate 18 is then reacted with Ac2O under K2CO3 as a base catalysis to generate intermediate 19. Intermediate 19 is deformylated under K2CO3 and MeOH as solvent reflux to obtain intermediate 20. Intermediate 20 undergoes nucleophilic substitution reaction with benzyl bromide to generate intermediate 21. The nitro group of the benzene ring is reduced by Pd / C and H2 to obtain intermediate 22. Using pyridine as an acid-binding agent, intermediate 22 is reacted with substituted benzenesulfonyl chloride to obtain a compound with the structural formula shown in formula (II). Alternatively, starting with 2-quinolinone, selective nitration with HNO3 and H2SO4 yields 6-nitroquinolinone. Under the condition of Cs2CO3 as a base, nucleophilic substitution reaction with substituted benzyl bromide or benzyl chloride yields an intermediate. The benzene ring substituted nitro group is selectively reduced with SnCl2 and then reacted with substituted benzenesulfonyl chloride under the condition of pyridine as a base to obtain a compound with the structural formula shown in formula (Ⅲ). Alternatively, starting with acridinone, selective nitration with HNO3 and H2SO4 yields 6-nitroacinone. After dehydrogenation under K2CO3 conditions, nucleophilic substitution with benzyl bromide yields intermediate 27. The nitro group on the benzene ring is selectively reduced with Pd / C and H2 to generate intermediate 28. Intermediate 28 is then reacted with substituted benzenesulfonyl chloride under pyridine as a base to prepare a compound with the structural formula shown in formula (Ⅳ). Alternatively, starting with 2-chloro-6-nitroquinoline, intermediate 30 is obtained through a nucleophilic substitution reaction with aniline; intermediate 30 is then subjected to Pd / C, H2 reduction of the nitro group to an amino group to obtain intermediate 31; intermediate 31 is then reacted with substituted benzenesulfonyl chloride under pyridine as a base to prepare a compound with the structural formula shown in formula (V).
4. The use of at least one of the sulfonamide quinoline derivatives as described in claim 1 or 2, or their pharmaceutically acceptable salts, prodrug molecules, stereoisomers, deuterated derivatives, and solvates in the preparation of glucocorticoid receptor modulators.
5. The use of at least one of the sulfonamide quinoline derivatives as described in claim 1 or 2, or a pharmaceutically acceptable salt thereof, a prodrug molecule, a stereoisomer, a deuterated derivative, and a solvate thereof, in the preparation of a medicament for treating autoimmune diseases.
6. The use according to claim 5, wherein the compound is ###0002### The autoimmune diseases mentioned are at least one of the following: Alzheimer's disease, Parkinson's disease, atherosclerosis, asthma and allergic airway inflammation, atopic dermatitis, amyotrophic lateral sclerosis, cryoinflammatory factor-related periodic fever syndrome, gout, glomerulonephritis, inflammatory bowel disease, non-alcoholic fatty liver disease and non-alcoholic lipoic hepatitis, autoimmune hepatitis, hypertension, myocardial infarction, multiple sclerosis or autoimmune encephalitis, inflammatory nephropathy, influenza, organ transplant rejection, stroke, silicosis, traumatic brain injury, sepsis, rheumatoid arthritis, obesity-related inflammation or insulin resistance, type I or type II diabetes, osteoarthritis and osteoporosis, myelodysplastic syndrome, and allergic skin reactions.
7. A pharmaceutical composition for treating an autoimmune disease, characterized by, It comprises at least one of the following as an active ingredient: a sulfonamide quinoline derivative as described in claim 1 or 2, or a pharmaceutically acceptable salt thereof, a prodrug molecule, a stereoisomer, a deuterated derivative, and a solvate, and a pharmaceutically acceptable carrier.
8. The pharmaceutical composition of claim 7, wherein The pharmaceutically acceptable salts are hydrochloride, benzenesulfonate, methylbenzenesulfonate, phosphate, maleate, sulfate, acetate, citrate, fumarate, or tartrate.
9. The pharmaceutical composition of claim 7, wherein The pharmaceutical composition is formulated as a gas, liquid, or solid preparation.
